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Purpose/Objective: This study proposed a method to estimate the 
beam-on time for prostate cancer patients treated on Tomotherapy 
when FW (field width), PF (pitch factor), modulation factor (MF) and 
treatment length (TL) were given. 
Materials and Methods: The study was divided into two parts: building 
and verifying the model. To build a model, 160 treatment plans were 
created for 10 patients. The plans differed in combination of FW, PF 
and MF. For all plans a graph of beam-on time as a function of TL was 
created and a linear trend function was fitted. Equation for each 
trend line was determined and used in a correlation model. Finally, 40 
plans verified the treatment time computation model - the real 
execution time was compared with our estimation and irradiation time 
calculated based on the equation provided by the manufacturer. 
Results: A linear trend function was drawn and the Pearson 
correlation coefficient r were calculated for each of the 8 trend lines 
corresponding to the adequate treatment plan. An equation to correct 
the model was determined to estimate more accurately the beam-on 
time for different MFs. Correlation was found to be high since for all 
plans r was higher than 0.98. The data showed that the estimation 
suggested by the manufacturer tended to underestimate the beam-on 
time on average by 52sec. However, differences of up to 154sec were 
observed. Whereas, the estimation based on the correlation model 
overestimated the treatment time on average by 14sec. In Figure 1B, 
an advantage of the correlation model might be observed, since the 
most frequent beam-on time differences were below 10% and the data 
were distributed almost symmetrically (skewness=– 0.08) which might 
suggest a good assessment of our model. 
 
  
Figure 1. Histogram of differences between real (from HT system) and 
estimated (from correlation model or manufacturer equation) beam-
on time in seconds (A) and percentage (B).  
 
Conclusions: Our study showed that the model can well predict the 
treatment time for a given TL, MF, FW and it can be used in clinical 
practice.  
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Purpose/Objective: To discuss key points identified during the 
commissioning of 6MV flattening filter free (FFF) and to identify 
treatment sites routinely treated using RapidArc© (Varian Medical 
Systems, Palo Alto) that could benefit from 6MVFFF. 
Materials and Methods: 6MVFFF was calibrated on the TrueBeam® 
linear accelerator (Varian Medical systems, Palo Alto) following the UK 
photon code of practice and the recommendations of Xiong et al 
(2008). Beam data was collected and the beam model configured in 
the Varian Eclipse TPS. The beam model was compared to measured 
data. Equipment routinely used for quality assurance, including the 
seven29 array (PTW, Freiburg), was tested in the high dose rate 
6MVFFF beam. To identify sites which may benefit from FFF a number 
of prostate and multi dose level head and neck patients were 
replanned using RapidArc© with 6MVFFF and 6MV flattened beams. All 
plans were optimised to produce clinically acceptable plans based on 
departmental protocols. For each plan the conformity index and 
homogeneity index were calculated and site specific organ doses were 
compared. 
Results: The 6MVFFF beam has been successfully calibrated with a 
correction of -0.5% being applied to kQ. The seven29 array with 
Octavius phantom can accurately measure dose at a dose rate of 
1400MU/min provided the measurement interval is adjusted to 200ms, 
but the QA BeamChecker™ Plus (Standard Imaging, United States) 
saturates at dose rates of 1400MU/min. However it is capable of 
accurately measuring at 1200MU/min.  
For standard prostate RapidArc treatments table one demonstrates 
there is no clinical benefit in using 6MVFFF over 6MV. All organs were 
within the departmental tolerances with no individual organ 
benefitting significantly from the FFF beam. For head and neck 
patients it seems there may be a benefit in using 6MVFFF. For organs 
further away from the PTV it is easier to meet the dose constraints 
and maximum doses in these organs are lower. This is due to the 
natural shape of the beam. For organs close to the PTV it is often 
possible to reduce the maximum dose as well.  
 
 
Conclusions: Further guidance on the calibration of these beams and 
possibly the development of a calibration procedure in FFF beams is 
necessary. Existing equipment can be successfully used in these high 
dose rate beams although it is sometimes necessary to limit the dose 
rate.  
Initial data suggests that FFF beams won’t benefit standard prostate 
treatments, but may help reduce the maximum dose to critical organs 
in head and neck treatments.  
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Purpose/Objective: Modern TPSs are coming with advanced dose 
calculation algorithms such as superposition. However, when using 
superposition algorithms it is more difficult to achieve ICRU 50 
recommendations (i.e. a minimum of 95% of the prescribed dose to 
the PTV) than with the old pencil beam convolution based algorithms 
due to the more accurate representation of the dose in heterogeneous 
media. The aim of this study was to determine the differences of dose 
calculations in lungs between two algorithms, and compare the 
calculations to measured doses. 
Materials and Methods: Semi-anthropomorphic phantom CIRS Thorax 
002 LFC was CT scanned and transferred to TPS. The phantom is 
elliptical in shape and represents an average human torso in 
proportion, density and two-dimensional structure. Plans were 
calculated according to IAEA TECDOC 1583 for verification of TPS, and 
measurements with ion chamber were conducted afterwards. Also, 
comparison of dose calculations for different clinical lung treatment 
plans were carried out for further 10 patients. Patient plans were 
calculated by both algorithms, but irradiated according to the results 
of the superposition algorithm. Also, old patient plans, clinically 
calculated and irradiated according to pencil beam calculations, were 
re-calculated by superposition, and differences evaluated. 
Results: The systematic dose overestimation by up to 15 % for the 
pencil beam convolution algorithm was recorded for all measurement 
points located inside the lung equivalent material. The range of 
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deviations was related to the beam energy, i.e. larger deviations were 
observed for the higher beam energy. The overall treatment time 
calculated with superposition was 5-7 % longer in comparison to the 
calculation of convolution, and the coverage of PTV, in terms of 95% 
isodose, was better (up to 18%). Hot spots were lower for 
superposition plans for both low and high energies. 
Conclusions: Convolution algorithms are not adequate for dose 
calculations in the presence of and inside low density 
inhomogeneities, while the superposition algorithm showed better 
agreement for all cases.Convolution algorithm overestimates the 
delivered dose, which leads to the underdosage of the target volume 
in reality. This applies both to lower energy and even more to higher 
energy beams. Differences between doses calculated with 
superposition and convolution algorithms are primarily due to changes 
in electron transport in the lungs, which is not adequately taken into 
account by convolution algorithm. Following these findings, and 
recommendations from the literature all lung patients is planned with 
superposition algorithm. 
Acknowledgement: The work has been supported by IAEA through the 
national SRB6006 and regional RER 6023 technical cooperation 
project. 
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Purpose/Objective: To evaluate the effect of 6, 15 MV and mixed 
energy (6&15MV) on intensity-modulated radiation therapy (IMRT) 
plans for prostate cancer using the equivalent uniform dose (EUD) and 
normal tissue complication probability (NTCP).  
Materials and Methods: In this study, immobilization and CT 
simulation were performed for 15 prostate cancer patients, as is 
routine for prostate cancer patients receiving IMRT in our department. 
The treatment position is supine with kneefix. Using the simulator 
lasers, patients were aligned and marked to define the coordinate 
system to be used for treatment planning. The patients were scanned 
in treatment position on Siemens Emotion Duo using 5-mm slice 
thickness. The data transferred to the treatment planning system. The 
determination of the 15 prostate cancer patient’s target volume and 
critical tissues are initially done by using CT images obtained in our 
clinic. After definition of the critical organs which are rectum, 
bladder and femoral heads, three different IMRT plans were done for 
each of 15 patients using 6 MV, 15 MV and mixed 6 and 15 MV energies 
using similar dose constraints and 8-fields setting. Gantry angles of 
225o,260o, 295o, 330o, 65o, 100oand 135o are used in our clinic for IMRT 
plans for prostate cancer. For the plan of mixed-energy, 15 MV photon 
beams at the gantry angles of 100oand 260o were used while 6 MV 
were used for the rest of the gantry angles.The dose distributions 
were similar for all plannings. Three plans were evaluated and 
compared by using EUD and NTCP.  
Results: For the bladder, rectum and both right and left femoral 
heads, the NTCP values were calculated less than %1 for the plannings 
with 6 MV, 15 MV and mixed energy plans. However, NTCP values to 
the bladder and rectum of mixed-energy plans were slightly lower 
than that of 6 MV and 15 MV plans. 
Conclusions: The study does not show any significant differences 
between plannings with 6 MV, 15 MV and mixed energies with respect 
to NTCP. Also there is no significant difference in the dose 
distribution. However, the results of this study show that by using 
mixed-energy in aprostate IMRT plan, the bladder and rectum doses 
can be slightly reduced and the plan quality can be improved.  
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Purpose/Objective: Due to the complexity of the IMRT dose 
distributions, a modification in the clinical practice such as contour 
definition or prescription may have a dosimetric impact and has to be 
evaluated. This situation occurs for some clinical trials. This study 
aimed at comparing dose distributions obtained for two groups of 
patients representative of clinical practice and a particular clinical 
trial. 
Materials and Methods: In our clinical practice, cancer prostate 
radiotherapy treatments consist in delivering 76Gy/38 fractions using 
IMRT. The following dosimetric objectives are considered for plan 
validation: PTV (D95%>95%), bladder wall (V65Gy<25%, V40Gy<50%), 
rectal wall (V70Gy<15%, V65Gy<25%, V38Gy<50%), and femoral heads 
(V50Gy<10%, V30Gy<50%). For a clinical trial, a new definition of 
contours and a new prescription were defined. Prescription was 
78Gy/39 fractions with the following dosimetric objectives: CTV 
(D99%>78Gy), PTV (D95%>74.1Gy, D1cc<81.9Gy), bladder and rectal 
walls (D30%<72.8Gy, D50%<54.3Gy), femoral heads (D5%<54.3Gy). 30 
patient treated between 2006 and 2012 were randomly selected from 
our database to create a control group. Mean number of MUs and 
homogeneity index ((D2%-D98%)/D50%) were calculated. For organs at 
risk, organs were delineated according to the clinical practice, and 
dose volume histogram values were reported. For the five first 
patients included in the clinical trial, contours and plans were 
validated following protocol recommendations. However, contours 
were also defined according to the clinical practice. For example, the 
bladder was contoured either only 18mm above the base of the 
prostate and in totality for clinical trial and clinical practice, 
respectively. For these 5 patients, usual dose volume histogram values 
were reported and compared to the control group. 
Results: Homogeneity indices were 0.05±0.01 and 0.10±0.02 for CTV 
and PTV respectively for the control group. They were slightly better 
for the study group: 0.04±0.01 and 0.07±0.01. These results showed a 
satisfactory target volume coverage whatever the protocol. Compared 
to the control group, number of MUs was 8% higher for the study 
group. For the bladder, the dose histogram values were reported as a 
function of the percentage of the overlap between the bladder and 
the PTV. Results obtained for the control group showed a very good 
reproducibility and robustness of IMRT prostate planning procedures. 
Values reported for the study group were similar to the control group 
despite the higher dose prescribed to the target volume. Similar 
results were obtained for rectum and femoral heads. 
Conclusions: This study showed that the clinical trial protocol led to 
dosimetric results similar to those obtained in our clinical practice 
despite the differences in contours and prescriptions. Physicians were 
therefore more confident to include patients in the clinical trial.  
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Purpose/Objective: This study was performedto examine the 
potential role of volumetric modulated arc therapy (VMAT) in 
comparison with intensity modulated radiotherapy (IMRT) for pelvic 
malignancies. 
Materials and Methods: Seven field dynamic IMRT and double arc 
VMAT plans were compared for ten pelvic cancer cases in terms of 
total monitoring units (MU), maximum dose, conformity index, 
uniformity or homogeneity index, integral dose and dose to normal 
structures. All the plans were created in eclipse version10 treatment 
planning system (TPS) and executed in Varian Clinax-iX linear 
accelerator through ARIA10 networking platform. Student’s paired t-
test was performed to compare the results. 
Results: Average conformity index of IMRTplan was 1.5+/1 0.12, but 
the VMAT plans achieved on an average of 1.38±0.04(p-value of 
0.016). Average uniformity index for VMAT plan was 1.05±0.01, but in 
IMRT it was 1.074±0.02 (p-value of 0.006). No significant difference 
was observed in maximum dose between IMRT and VMAT (p-value of 
0.854). The integral dose (p-value of 0.003) and normal tissues dose 
was found less in VMAT plans compared to IMRT plans. The average MU 
needed to deliver the dose of 200 cGy per fraction was 415±33 for 
VMAT plans, while for IMRT plan it was 743±92(p-value of 0.000). 
VMAT plans involve two full rotation of gantry, so that it gives more 
freedom in dose modulation. In VMAT, image guidance improves 
tumour targeting and the fast delivery in less than 2-5 minutes helps 
to minimise the probability of intra fractional movement of target and 
critical organs. The reduction in treatment time gives more comfort 
and less stress to patients. Significant reduction of MU in VMATplans 
compared to IMRT may result in less leakage and scattered radiation 
and low overall peripheral dose.  
Conclusions: The comparative study with VMAT versus IMRT employed 
in pelvic cancers proved, better normal tissues sparing and better 
target coverage by VMATcompared to IMRT technique. 
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Quality of radiation treatment planning in postmastectomy 
patients- comparison of 3D versus 2D plans 
